A series of pre-clinical studies have shown that 177Lu-HH1 successfully binds to both lymphoma cell lines and biopsies from NHL patients, indicating that targeting of the CD37 antigen with HH1 is clinically relevant [7]. This evidence concerns the gene CD37 and lymphoma.